Evidence Hub

Is an Opioid Prescription Necessary after Joint Replacement in 2026?

Anjali Malhotra, Kayleigh Corrado, Brian Fuller, Andrew Wickline

Journal of Orthopaedic Experience & Innovation, 2026

210 participants · 1 citation

Abstract

Background Orthopedic surgeons account for the most perioperative opioid prescriptions among all surgical specialties. Despite the growing emphasis on multimodal analgesia, consistent opioid-free recovery after total joint arthroplasty (TJA) has not been widely demonstrated. Suzetrigine (Journavx™), a peripherally acting sodium-channel inhibitor, represents a novel non-opioid option for postoperative pain. This study evaluated whether adding suzetrigine to a standardized, second-generation multimodal protocol was associated with high rates of opioid-free recovery after total hip arthroplasty (THA) and total knee arthroplasty (TKA). Methods A consecutive series of primary THA and TKA patients performed by a single surgeon were retrospectively reviewed. All patients received suzetrigine 100 mg preoperatively and 50 mg every 12 hours postoperatively for 2 weeks. Preoperative opioid exposure and postoperative opioid prescriptions were documented. Group comparisons were performed using t-tests and chi-square testing and multivariable analysis. Results Overall, 210 of 236 patients (89.0%) did not fill an opioid prescription following surgery. Preoperative opioid use was found in 19 patients (8.1%), and postoperative opioid prescriptions were written for 26 patients (11.0%). TKA patients were more likely to require opioids than THA patients (80.8% vs 19.2%, p = 0.001). Among opioid-naive patients, opioid-free recovery occurred in 88.7% of TKA patients (94/106) and 98.2% of THA…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free